These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31652306)

  • 1. cGMP signalling in cardiomyocyte microdomains.
    Bork NI; Molina CE; Nikolaev VO
    Biochem Soc Trans; 2019 Oct; 47(5):1327-1339. PubMed ID: 31652306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microdomain switch of cGMP-regulated phosphodiesterases leads to ANP-induced augmentation of β-adrenoceptor-stimulated contractility in early cardiac hypertrophy.
    Perera RK; Sprenger JU; Steinbrecher JH; Hübscher D; Lehnart SE; Abesser M; Schuh K; El-Armouche A; Nikolaev VO
    Circ Res; 2015 Apr; 116(8):1304-11. PubMed ID: 25688144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct submembrane localisation compartmentalises cardiac NPR1 and NPR2 signalling to cGMP.
    Subramanian H; Froese A; Jönsson P; Schmidt H; Gorelik J; Nikolaev VO
    Nat Commun; 2018 Jun; 9(1):2446. PubMed ID: 29934640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transgenic mice for real-time visualization of cGMP in intact adult cardiomyocytes.
    Götz KR; Sprenger JU; Perera RK; Steinbrecher JH; Lehnart SE; Kuhn M; Gorelik J; Balligand JL; Nikolaev VO
    Circ Res; 2014 Apr; 114(8):1235-45. PubMed ID: 24599804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cGMP Signaling in the Cardiovascular System-The Role of Compartmentation and Its Live Cell Imaging.
    Bork NI; Nikolaev VO
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29534460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. cGMP-cAMP interplay in cardiac myocytes: a local affair with far-reaching consequences for heart function.
    Stangherlin A; Zaccolo M
    Biochem Soc Trans; 2012 Feb; 40(1):11-4. PubMed ID: 22260658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β
    Schobesberger S; Wright PT; Poulet C; Sanchez Alonso Mardones JL; Mansfield C; Friebe A; Harding SE; Balligand JL; Nikolaev VO; Gorelik J
    Elife; 2020 Mar; 9():. PubMed ID: 32228862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitric oxide synthase and cyclic GMP signaling in cardiac myocytes: from contractility to remodeling.
    Hammond J; Balligand JL
    J Mol Cell Cardiol; 2012 Feb; 52(2):330-40. PubMed ID: 21843527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac cGMP Signaling in Health and Disease: Location, Location, Location.
    Cuello F; Nikolaev VO
    J Cardiovasc Pharmacol; 2020 May; 75(5):399-409. PubMed ID: 32040034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic nucleotide imaging and cardiovascular disease.
    Berisha F; Nikolaev VO
    Pharmacol Ther; 2017 Jul; 175():107-115. PubMed ID: 28216026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visualising and understanding cGMP signals in the cardiovascular system.
    Feil R; Lehners M; Stehle D; Feil S
    Br J Pharmacol; 2022 Jun; 179(11):2394-2412. PubMed ID: 33880767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of phospholamban in cyclic GMP mediated signaling in cardiac myocytes.
    Zhang Q; Scholz PM; Pilzak A; Su J; Weiss HR
    Cell Physiol Biochem; 2007; 20(1-4):157-66. PubMed ID: 17595525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Live Cell Imaging of Cyclic Nucleotides in Human Cardiomyocytes.
    Beneke K; Molina CE
    Methods Mol Biol; 2022; 2483():195-204. PubMed ID: 35286677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDE2 at the crossway between cAMP and cGMP signalling in the heart.
    Weber S; Zeller M; Guan K; Wunder F; Wagner M; El-Armouche A
    Cell Signal; 2017 Oct; 38():76-84. PubMed ID: 28668721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sildenafil Does Not Prevent Heart Hypertrophy and Fibrosis Induced by Cardiomyocyte Angiotensin II Type 1 Receptor Signaling.
    Straubinger J; Schöttle V; Bork N; Subramanian H; Dünnes S; Russwurm M; Gawaz M; Friebe A; Nemer M; Nikolaev VO; Lukowski R
    J Pharmacol Exp Ther; 2015 Sep; 354(3):406-16. PubMed ID: 26157043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-(1-7) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3',5'-cyclic monophosphate-dependent pathway.
    Gomes ER; Lara AA; Almeida PW; Guimarães D; Resende RR; Campagnole-Santos MJ; Bader M; Santos RA; Guatimosim S
    Hypertension; 2010 Jan; 55(1):153-60. PubMed ID: 19996065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Species- and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels.
    Fischmeister R; Castro L; Abi-Gerges A; Rochais F; Vandecasteele G
    Comp Biochem Physiol A Mol Integr Physiol; 2005 Oct; 142(2):136-43. PubMed ID: 15927494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances and techniques to measure cGMP in intact cardiomyocytes.
    Götz KR; Nikolaev VO
    Methods Mol Biol; 2013; 1020():121-9. PubMed ID: 23709029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of cyclic GMP hydrolysis with zaprinast reduces basal and cyclic AMP-elevated L-type calcium current in guinea-pig ventricular myocytes.
    Ziolo MT; Lewandowski SJ; Smith JM; Romano FD; Wahler GM
    Br J Pharmacol; 2003 Mar; 138(5):986-94. PubMed ID: 12642401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of metabolism by cGMP.
    Pfeifer A; Kilić A; Hoffmann LS
    Pharmacol Ther; 2013 Oct; 140(1):81-91. PubMed ID: 23756133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.